Abstract. Mild hypothermia (MH) and edaravone (EDA) exert neuroprotective effects against cerebral ischemia/reperfusion (I/R) injury through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway. However, whether MH and EDA exert synergistic effects against cerebral I/R injury remains unknown. The aim of the present study was to investigate the effects and mechanism of action of MH in combination with EDA in cerebral I/R injury. A rat cerebral I/R injury model was constructed by middle cerebral artery occlusion (MCAO) followed by reperfusion, and the mice were treated by MH, EDA or the inhibitor of the Nrf2 signaling pathway brusatol (Bru). It was observed that mice treated by MCAO had higher neurological deficit scores and oxidative stress levels, and low spatial learning and memory capacity; moreover, the CA1 region of the hippocampi of the mice exhibited reduced neuronal density and viability, and reduced mitochondrial dysfunction. However, MH in combination with EDA reversed the effects of MCAO, which were blocked by Bru injection. The levels of glutathione (GSH), GSH peroxidase, catalase and superoxide dismutase in rat ischemic hemisphere tissues were reduced by Bru. Western blotting demonstrated that the combined treatment with MH and EDA promoted the nuclear localization of Nrf2, and increased the levels of NAD(P)H quinone oxidoreductase and heme oxygenase (HO)-1. In conclusion, MH combined with EDA exerted synergistic neuroprotective effects against cerebral I/R injury involving changes in the Nrf2/HO-1 pathway.

Introduction

Stroke, which is characterized by loss of neurological function caused by ischemia of the brain, intracerebral hemorrhage or subarachnoid hemorrhage (1), is associated with high morbidity and mortality rates (2,3). It has been demonstrated that, by inducing excitotoxicity, cerebral ischemia/reperfusion (I/R) injury is a critical factor responsible for poor prognosis in patients with ischemic stroke. Stroke disrupts calcium ion homeostasis, causes overproduction of free radicals and inflammatory cytokines, and promotes cell apoptosis (4). Currently, although thrombolytic, endovascular and adjuvant novel therapies have been developed for stroke (5,6), they have been proven insufficient in achieving the desired outcome. Therefore, a better understanding of the mechanisms underlying the development of cerebral I/R injury is required.

Mild hypothermia (MH) exerts neuroprotective effects against cerebral ischemia. It was previously reported that MH reduces brain hemorrhage and blood-brain barrier disruption after stroke (7), and that it may alleviate cerebral ischemic injury in diabetic patients through promoting autophagy and inhibiting pyroptosis (8). Researchers also demonstrated that inhibition of Notch3 and Notch4 signaling is involved in the protective effect of MH against cerebral ischemic injury (9). Moreover, MH promotes long-term white matter integrity and inhibits neuroinflammation in mice with ischemic brain injury (10). These previous findings indicate that MH may be of therapeutic value in cerebral I/R injury.

Edaravone (EDA; 3-methyl-1-phenyl-2-pyrazolin-5-one) is a free radical scavenger. Evidence has indicated that EDA protects the brain against cerebral ischemic injury, and it may inhibit microglia-mediated neuroinflammation in rats with cerebral ischemic injury (11). It has also been demonstrated that EDA protects neuronal cells from ischemic injury by inhibiting the translocation of 5-lipoxygenase to the nuclear membrane, thereby blocking the 5-lipoxygenase signaling pathway (12). Moreover, EDA combined with MH significantly improves neuroprotection in rats exposed to hypoxia (13).
Thus, it was inferred that EDA in combination with MH may exert a synergistic effect against cerebral I/R injury.

The transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) is a central modulator in multiple biochemical processes, such as redox, protein and metabolic homeostasis. Nrf2-based therapeutics have been developed for treating various cardiovascular, kidney and liver diseases (14). It was previously demonstrated that EDA protects the nervous system from toxicity through activating the Nrf2 signaling pathway (15). However, whether the positive effects of EDA on cerebral I/R injury are mediated through the activation of the Nrf2 signaling pathway remains unclear.

Therefore, in the present study, a cerebral I/R model in rats was constructed to explore the potential synergistic effects and the mechanism underlying the combination of EDA with MH in I/R injury. In addition, brusatol (Bru), an inhibitor of the Nrf2 signaling pathway, was also used to investigate the effects of Nrf2 signaling on I/R injury.

Materials and methods

**MCAO model and drug treatment.** A total of 60 healthy adult Sprague-Dawley male rats, 9-10 weeks old and weighing 300-320 g, were purchased from Vital River Laboratories Co., Ltd. All the animals were housed under specific pathogen-free conditions with a 12-h dark/light cycle at 25°C, and fed standard food and aseptic water. All the experiments were approved by the Institutional Animal Ethics Committee of Hainan Medical University (approval no. C2017051992A).

Focal I/R in each rat was created by middle cerebral artery occlusion (MCAO). Briefly, the rats were anesthetized by 3% isoflurane at 50 mg/kg body weight (1235809; Sigma-Aldrich; Merck KGaA) administered by intraperitoneal injection, while monitoring the heart rate. Then, a 0.18 mm nostril suture with a spherical end (diameter 0.18 mm) was inserted into the brain of each rat following the direction of the CCA and stopped when the thread entered the middle cerebral artery (MCA). After occlusion for 120 min, the thread was dismantled to allow reperfusion for 24 h. The rats treated by MCAO were then randomly divided into 5 groups as follows: MCAO, MCAO + MH, MCAO + EDA, MCAO + MH + EDA and MCAO + MH + EDA + Bru groups (n=10 rats per group). Furthermore, 10 rats in the sham group were treated in a similar manner but without arterial occlusion. Immediately after MCAO, ice was placed under the skull of the rats treated by MH, with the temperature of the temporalis muscle maintained at 32-34°C for 2 h. EDA (M70800; Sigma-Aldrich; Merck KGaA) and Bru (SML1868, Sigma-Aldrich; Merck KGaA) were diluted in physiological saline (16,17), and 3.0 mg/kg EDA or 1.0 mg/kg Bru were immediately intraperitoneally injected into the rats after MCAO. No rats died during the experiments. The rats were euthanized and their brain tissues were collected, cut into 3-mm sections, and infarct size calculation.

**Brain 2,3,5-triphenyltetrazolium chloride (TTC) staining and infarct size calculation.** The rats were euthanized and their brain tissues were collected, cut into 3-mm sections, and placed in a water bath with 2% TTC solution for 30 min at 37°C in the dark. The stained sections were photographed and then analyzed by AlphaImager HP 1.0 software (Alpha Innotech Corp) to calculate the infarct area rates.

**Immunofluorescence staining.** Immunofluorescent staining of NeuN was conducted to determine the neuronal density in the ischemic hippocampi. Briefly, the rats in each group were subjected to deep anesthesia 3 days after MCAO. The brain tissues were isolated, exposed to 4% paraformaldehyde (PFA) at 4°C overnight and then cryoprotected in 30% sucrose solution at 4°C overnight. When tissues sank to the bottom, they were frozen in optimal cutting temperature compound, and 25-µm brain sections were prepared using a Leica microtome (CM3050 S; Leica Microsystems GmbH). Next, anti-rat NeuN antibody (1:500; cat. no. PA5-78499, Thermo Fisher Scientific, Inc.) was incubated with free-floating sections. Subsequently, secondary antibody conjugated with Alexa Fluor® Plus 488 (cat. no. A32731, Thermo Fisher Scientific, Inc.) was then incubated with the sections at 25°C for 2 h. The images were captured using a confocal laser scanning microscope (CLSM; LSM 510 META, Carl Zeiss AG), with five fields examined for each sample (magnification, x400). Neuronal changes were quantified against sham control or other groups.

**Barnes maze task.** Barnes maze task was performed to examine the spatial learning and memory capacity of the rats. Briefly, the tests were conducted 11 days after MCAO. During testing, the time that each rat spent on finding the hidden escape box was recorded as escape latency. At 12 days after MCAO, the escape box was removed, and the time that the rats spent on finding the target quadrant within 90 sec was recorded as quadrant occupancy. The behavioral traces of each rat were recorded by a camera and analyzed by ANY-maze 4.8 video tracking software (Stoelting Co.).

**MitoTracker Red staining.** Mitochondrial membrane potential (MMP) was detected using MitoTracker Red staining, as previously described (12). Briefly, MitoTracker® Red CMXRos (50 ng/ml in 100 µl saline; C1049, Beyotime Institute of Biotechnology) was injected via the tail vein into the rats 5 min before euthanasia. Then, the brain tissues were isolated and fixed in 4% PFA at 4°C. Hippocampal tissue were cut into 25-µm sections and stained by DAPI (D8417; Sigma-Aldrich; Merck KGaA) at 37°C for 10 min. Images were then captured using a Zeiss CLSM (Carl Zeiss AG), and analyzed by LSM 510 META imaging software, version 2.01 (Carl Zeiss AG).

**Oxidative stress parameters.** For detecting oxidative stress parameters in rat ischemic hemisphere tissues, lipid peroxidation assay kit (MAK085; Sigma-Aldrich; Merck KGaA),
glutathione (GSH) assay kit (CS0260; Sigma-Aldrich; Merck KGaA), GSH peroxidase (PX) assay kit (S0058, Beyotime Institute of Biotechnology), catalase (CAT; S0051, Beyotime Institute of Biotechnology) and superoxide dismutase (SOD; S0109, Beyotime Institute of Biotechnology) were purchased and performed according to the manufacturer's instructions. Briefly, the tissue (~10 mg) was homogenized on ice in 300 µl cell lysis buffer (MCL1; Sigma-Aldrich; Merck KGaA). For the detection of malondialdehyde (MDA) content, insoluble materials and proteins were removed from homogenized tissues by centrifugation at 13,000 x g at 4°C for 10 min; 150 µl water containing 3 µl butylated hydroxyltoluene (100X) and 2 N perchloric acid was then added to the tissues and vortexed at 25°C. Next, 200 µl supernatant was mixed with 600 µl thioarbituric acid solution and incubated at 95°C for 60 min. Subsequently, 200 µl reaction mixture were added into a 96-well plate and the absorbance at 532 nm was determined by a microplate reader (PLUS 384, Molecular Devices, LLC). For the detection of GSH, 5 µl homogenized tissue was deproteinized using 5 µl 5% 5-sulfsalicylic acid solution. Subsequently, 10 µl mixture was mixed with 150 µl working solution consisting of 1X assay buffer, enzyme solution and DTNB, and incubated for 5 min at 25°C. Next, 50 µl NADPH (0.16 mg/ml) was added into the mixture at 25°C, and the absorbance at 412 nm was detected. For the detection of GSH peroxidase (GSH-PX), 180 µl GSH-PX buffer, 5 µl of diluted sample, 11 µl GSH-PX working solution and 4 µl 15 mM superoxide (Cum-OOH) were added into a 96-well plate and incubated for 20 min at 25°C, and the absorbance at 340 nm was determined. For the detection of CAT, 10 µl diluted sample were incubated with 10 µl 250 mM hydrogen peroxide and 30 µl detection buffer at 25°C for 5 min, and then the absorbance at 520 nm was read. For the detection of SOD, 20 µl diluted sample were incubated with 160 µl NBT solution and 20 µl reaction regent at 25°C for 30 min, and the absorbance at 560 nm was read.

Mitochondrial dysfunction detection. Mitochondrial dysfunction in the ischemic hemisphere tissues of the rats was evaluated by detecting the activity of cytochrome c using a cytochrome c apoptosis assay kit (K257-100, BioVision, Inc.). The cytochrome c released from mitochondria was detected by western blotting using the cytochrome c antibody in the kit. The relative content of cytochrome c in each group was determined against that in the sham group. Caspase-3 enzyme activity in rat ischemic hemisphere tissues was measured using a commercial kit (CASP3C; Sigma-Aldrich; Merck KGaA).

Western blotting. After treatment for 24 h, the ischemic brain tissues were separated and homogenized on ice. Nuclear and cytoplasmic proteins were extracted using nuclear and cytoplasmic extraction kits (SC-003, Invent Biotechnologies, Inc.). Equal amounts of protein (50 µg) were separated on 12% SDS-PAGE and transferred onto PVDF membranes (EMD Millipore). After blocking the membranes for 1 h in 5% non-fat milk, the bands were exposed to primary antibodies against Nrf2 (1:2,000, cat. no. ab137550, Abcam), heme oxygenase-1 (HO-1; 1:2,000; cat. no. ab13243, Abcam), NAD(P)H quinone oxidoreductase (NQO1; 1:2,000, cat. no. ab28947, Abcam), β-actin (1:5,000, cat. no. ab8226, Abcam) and histone H3 (1:5,000, cat. no. ab1791, Abcam) at 4°C overnight. Next, the bands were incubated with anti-rabbit IgG (cat. no. SA00001-2, ProteinTech Group, Inc.) or anti-mouse IgG (cat. no. SA00001-1, ProteinTech Group, Inc.) for 2 h. The bands were finally developed by ECL (Pierce; Thermo Fisher Scientific, Inc.).

Primary culture of hippocampal neurons. Briefly, the CA1 region of the rat hippocampus was rapidly separated 3 days after MCAO and sectioned, and then exposed to trypsin for 30 min at 37°C. After that, the digested cells were cultured in DMEM (11965084; Thermo Fisher Scientific, Inc.) with 10% FBS (10100147; Gibco; Thermo Fisher Scientific, Inc.), then transferred to an incubator with 5% CO₂ at 37°C for 2 h. The culture medium was replaced once every 2 days. After culture for 24 h, hippocampal neurons were used for the subsequent experiments. The purity of neurons was determined by immunofluorescence staining of NeuN.

Cell viability. The viability of hippocampal neurons was measured by MTT assay. Briefly, the neurons (2,000 cells/well) were cultured in 96-well culture plates for 24 h. Then, MTT solution (5 mg/ml) was added into each well at 37°C for 4 h. Next, MTT was removed, and 150 µl DMSO were added into the wells to solubilize purple formazan crystals. Absorbance at 570 nm was then read using a microplate reader (PLUS 384, Molecular Devices, LLC).

Statistical analysis. Statistical data were analyzed using SPSS 19.0 (SPSS Inc.) and are shown as mean ± standard deviation. Statistical differences were analyzed by one-way analysis of variance followed by Tukey's multiple comparisons test. P<0.05 was considered to indicate statistically significant differences.

Results

Effects of MH, EDA and Bru on neuronal survival in the CA1 region of the rat hippocampus after MCAO. The neurological deficits were evaluated by the five-point scale 24 h after I/R, and the results revealed that the neurological deficit score of the rats subjected to MCAO was higher compared with those in the sham group (P<0.001, Fig. 1A). The neurological deficit scores of the rats treated by MH or EDA were reduced compared with those in the MCAO group (P<0.01, Fig. 1A). The neurological deficit score was the lowest in rats treated by MCAO, MH and EDA, whereas the protective effects of MH and EDA on the nervous system of rats injected with the Nrf2 pathway inhibitor Bru were significantly reduced (P<0.001, Fig. 1). Furthermore, immunofluorescence staining and a neuronal cell marker, NeuN, were used to analyze neuronal survival in the CA1 region of the rat hippocampus after MCAO. As shown in Fig. 1B and C, the number of surviving neurons was reduced in the MCAO group, but was increased in the MCAO + MH and MCAO + EDA groups (Fig. 1B and C). In addition, the rats co-treated with MH and EDA exhibited a more marked recovery of neuronal number after I/R, while Bru reversed the protective effects of MH and EDA (P<0.001, Fig. 1B).
Effects of MH, EDA and Bru on spatial learning, memory and mitochondrial function of the rats after MCAO treatment.

The escape latency and quadrant occupancy were evaluated by performing the Barnes maze task to explore the effects of MH, EDA and Bru on spatial learning and memory capacity of the rats after MCAO treatment. It was observed that the rats in the MCAO group spent a longer time on finding the hidden escape box (escape latency) compared with those in the sham group ($P<0.001$, Fig. 2A), whereas treatment with MH or EDA alone, or combined treatment with MH and EDA, could significantly shorten the escape latency compared with rats in the MCAO group ($P<0.001$, Fig. 2A). In addition, Bru injection increased the escape latency in rats treated by MH and EDA ($P<0.001$, Fig. 2A). The rats in the MCAO group spent a shorter time (quadrant occupancy) in the target quadrant compared with those in the sham group ($P<0.001$, Fig. 2B). However, MH and EDA increased the quadrant occupancy of the rats ($P<0.001$, Fig. 2B), and Bru injection blocked the effect of co-treatment with MH and EDA ($P<0.001$, Fig. 2A). The rats in the MCAO group spent a shorter time (quadrant occupancy) in the target quadrant compared with those in the sham group ($P<0.001$, Fig. 2B). However, MH and EDA increased the quadrant occupancy of the rats ($P<0.001$, Fig. 2B), and Bru injection blocked the effect of co-treatment with MH and EDA ($P<0.001$, Fig. 2A).

MitoRed fluorescence staining was performed to detect the MMP, and the data indicated that MCAO reduced the fluorescence intensity of MMP, which indicated mitochondrial depolarization and collapse of the MMP, whereas MH and EDA increased the fluorescence intensity. Additionally, co-treatment with MH and EDA caused a more significant increase of fluorescence intensity compared with either treatment alone ($P<0.001$, Fig. 2C and D), which, however, was reduced by Bru injection ($P<0.001$, Fig. 2C and D).

Effects of MH, EDA and Bru on the levels of oxidative stress biomarkers, neuronal viability, cytotoxicity and caspase-3 activity. Oxidative stress is involved in cerebral I/R. Thus, oxidative stress was further assessed by detecting the levels of MDA, GSH, GSH-PX, CAT and SOD in ischemic hemisphere tissues (Fig. 3D and E). The results demonstrated that the level of MDA was increased in the MCAO group compared with that in the sham group, while MH or EDA treatment, or MH and EDA co-treatment, could partly reverse the increase in MDA content caused by MCAO ($P<0.001$, Fig. 3A). Additionally, Bru treatment reversed the effect of co-treatment with MH and EDA on MDA levels ($P<0.001$, Fig. 3A). Furthermore, the levels of GSH, GSH-PX, CAT and SOD in rat ischemic hemisphere tissues were reduced by MCAO, but increased by MH and EDA treatment or co-treatment ($P<0.001$, Fig. 3B-E). Additionally, the levels of GSH, GSH-PX, CAT and SOD in rat ischemic hemisphere tissues were reduced in
the MCAO + MH + EDA + Bru group compared with those in the MCAO + MH + EDA group (P<0.001, Fig. 3B-E). The primary hippocampal neurons were collected from the tissues of the rats in different groups, and the cell viability was measured by the CCK-8 assay. The result demonstrated that MCAO reduced the viability of primary hippocampal neurons, which, however, was increased by MH and EDA treatment or their co-treatment. Moreover, it was observed that Bru injection suppressed the effects of MH and EDA (P<0.05, Fig. 3F). Furthermore, the activity of cytochrome c oxidase and caspase-3 in the mitochondrial fraction was detected, and the data demonstrated that MCAO increased the levels of cytochrome c oxidase and caspase-3, while MH and EDA weakened the effect of MCAO; moreover, Bru treatment blocked the effects of MH and EDA on cytochrome c oxidase and caspase-3 activities (P<0.001, Fig. 3G and H).

Effects of MH, EDA and Bru on the Nrf2/HO-1 pathway. The Nrf2 pathway is known to act protectively against oxidative stress. The expressions of cytoplasmic Nrf2 (cNrf2), nuclear Nrf2 (nNrf2), and those of its downstream genes HO-1 and NQO1 in rat ischemic hemisphere tissues were measured by western blotting. The data demonstrated that MCAO significantly increased the expression of cNrf2 (P<0.001) and slightly increased the expressions of Nrf2, HO-1 and NQO1 (P<0.01 or P<0.001, Fig. 4A-E). In addition, MH and EDA markedly increased the levels of HO-1, NQO1 and nNrf2, and simultaneously reduced the level of cNrf2, as compared with the MCAO group (P<0.001, Fig. 4A-E). The combined treatment with MH and EDA enhanced the effects caused by treatment with either MH or EDA alone on the Nrf2/HO-1 pathway, whereas these effects were reversed by Bru treatment (P<0.05 or P<0.001, Fig. 4A-E).

Discussion
It has been demonstrated that MH used together with other drugs or treatments may enhance the protective effects of MH against cerebral I/R injury. For example, a recent research revealed that MH with bone mesenchymal stem cell transplantation improved the prognosis of rats with cerebral ischemia (19). Combined therapy with phenothiazines and MH also enhanced neuroprotection in ischemic rats through regulating the PI3K/Akt pathway (20). It has also been reported that the Notch inhibitor DAPT combined with MH exerted a synergistic effect on post-stroke seizures (21). It was reported that MH in combination with phenothiazine drugs achieved a better long-term motor performance after acute stroke (22). Moreover, MH used with hydrogen sulfide treatment suppressed apoptosis and pathological injury of hippocampi of rats with cerebral I/R injury (23). These findings indicated that MH combined with other treatments may be a promising therapy in the management of cerebral I/R injury. The present study demonstrated that the neurological deficit score was significantly reduced and neuronal density was increased in the CA1 region of the rat hippocampi, suggesting that EDA combined with MH exerted a synergistic effect against I/R injury.

Although neurological deficit score evaluation and Barnes maze task test were performed, it may be a limitation.

Figure 2. Effects of MH, EDA and Bru on spatial learning, memory and mitochondrial function in rats subjected to MCAO. (A and B) The escape latency and quadrant occupancy of the rats were evaluated by Barnes maze task on day 12 after MCAO; n=10 mice per group. (C and D) Representative confocal microscopy images and statistical analysis of MitoRed fluorescence staining. Scale bar: 20 µm. Magnification, x400. ***P<0.001 vs. sham. ^^^P<0.001 vs. MCAO. **P<0.01 vs. MCAO + MH + EDA. MCAO, middle cerebral artery occlusion; MH, mild hypothermia; EDA, edaravone; Bru, brusatol.
that the TTC dying method was not used to assess the brain infarct area. The hippocampus is responsible for spatial learning and memory (24), which may be disturbed when the hippocampus sustains cerebral I/R injury (25). Therefore, the Barnes Maze task that helps evaluate spatial learning and memory ability was performed in the present study, and it was observed that EDA combined with MH could improve the spatial learning and memory ability of rats with cerebral I/R injury. MitoRed fluorescence staining was used to evaluate MMP. Under normal physiological conditions, mitochondria with high MMP can be marked by MitoTracker Red CMXRos, while MMP is reduced in mitochondrial dysfunction and therefore cannot be marked by MitoTracker Red CMXRos under pathological conditions or when cell apoptosis occurs. The present study demonstrated that mitochondrial dysfunction in rat hippocampi was induced by MCAO, but was significantly restored by the combined therapy of EDA with MH.

The CAT, SOD, GSH and GSH-PX enzymes are involved in the antioxidant defense system against cell oxidative stress (26), and MDA is indicative of IR-induced mitochondrial oxidative damage (27). In the present study, it was observed that MDA was increased, but CAT, SOD, GSH and GSH-PX were reduced in rats subjected to MCAO, suggesting that mitochondrial oxidative damage was induced by cerebral I/R injury. Importantly, restoration of dysregulated MDA, CAT, SOD, GSH and GSH-PX levels was detected in rats treated by MCAO and in those treated by combined EDA and MH. Thus, it may be inferred that EDA combined with MH alleviated the mitochondrial dysfunction induced by cerebral I/R.

Neurogenesis may be enhanced under pathological conditions, including cerebral ischemic injury, and it promotes repair of brain injury after stroke. It was demonstrated that neurogenesis can be suppressed by EDA in rats with cerebral I/R injury (28). However, it has also been shown that EDA
protects hippocampal neurons pre- and post-treatment and enhances neurogenesis after global cerebral ischemia (29).

In the present research, the viability of neurons separated from the CA1 region of the hippocampus was increased by MCAO, but was suppressed by MH and EDA. In addition, the increased activities of cytochrome c and caspase-3 were partially reversed by the combination of MH with EDA in rats with cerebral I/R. I/R induces dysfunction of mitochondria and reduces cytochrome c oxidase activity in rat hippocampal neurons (30,31). Increased activity of cytochrome c increases oxidative stress and cell apoptosis. Caspase-3 is considered to be a cell apoptosis marker; thus, it was inferred that MCAO may promote neurogenesis and increase the levels of apoptosis-associated factors, whereas MH and EDA may inhibit this process. It should be noted that the effect of the combined therapy with MH and EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

In the present research, the viability of neurons separated from the CA1 region of the hippocampus was increased by MCAO, but was suppressed by MH and EDA. In addition, the increased activities of cytochrome c and caspase-3 were partially reversed by the combination of MH with EDA in rats with cerebral I/R. I/R induces dysfunction of mitochondria and reduces cytochrome c oxidase activity in rat hippocampal neurons (30,31). Increased activity of cytochrome c increases oxidative stress and cell apoptosis. Caspase-3 is considered to be a cell apoptosis marker; thus, it was inferred that MCAO may promote neurogenesis and increase the levels of apoptosis-associated factors, whereas MH and EDA may inhibit this process. It should be noted that the effect of the combined therapy with MH and EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.

Nrf2 is a regulator of endogenous antioxidant defense and may be a potential target for oxidative stress in stroke (32). Nrf2 induces HO-1 expression and release of GSH to resist oxidative stress (33). It was reported that BRCA1 protects neurons from cerebral I/R injury through activating the Nrf2-associated antioxidant pathways (34). It has been reported that EDA enhances the oxidant defense capacity in brain tissue through promoting Nrf2/HO-1 signaling (35). MH was also reported to protect cerebral cortex and hippocampus neurons from cerebral I/R injury through the Nrf2/ARE pathway (36). In the present study, by injecting the Nrf2 pathway inhibitor Bru into rats treated by MH combined with EDA, it was observed that the protective effect of MH combined with EDA on cell apoptosis require further investigation.
of downstream target genes, such as HO-1 (37). The present study revealed that nuclear location of Nrf2 was increased and the expression of the Nrf2 downstream genes NQO1 and HO-1 was upregulated in the treated by MH combined with EDA.

In conclusion, a rat cerebral ischemia model was constructed in the present study, and demonstrated that combined treatment with MH and EDA improved rat neurological function and increased neuronal survival. In addition, the Nrf2 pathway inhibitor, Bru, could block the protective effect of MH and EDA. These findings indicated that MH combined with EDA exert a synergistic effect against cerebral I/R injury through the Nrf2/HO-1 pathway. However, a limitation of the present study was that there was no detection of more indicators of oxidative stress, and further research on these findings is required.

Acknowledgements
Not applicable.

Funding
The present study was supported by the Hainan Provincial Health and Family Planning Research Project (grant no. 18A200002), the Hainan Provincial Higher Education Research Project (grant no. Hnky2018-50) and the National Natural Science Foundation of China (grant no. 81660270).

Availability of data and materials
The data sets generated and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions
Substantial contributions to conception and design: HY and ZW; data acquisition, data analysis and interpretation: XW, CG, RL, FK and MD; drafting the article and critically revising it for important intellectual content: HY and ZW. All the authors have read and approved the final version to be published and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of the work are appropriately investigated and resolved.

Ethics approval and consent to participate
All the animal experiments were approved by the Institutional Animal Ethics Committee of Hainan Medical University (no. C2017051922A).

Patient consent for publication
Not applicable.

Competing interests
All the authors declare that they have no competing interests.

References
1. Alkhachroum Am, Miller B, Chami T, Tatsuoka C and Sila C: A troponin study on patients with ischemic stroke, intracerebral hemorrhage and subarachnoid hemorrhage: Type II myocardial infarction is significantly associated with stroke severity, discharge disposition and mortality. J Clin Neurosci 64: 83-88, 2019.
2. Feigin VL, Mensah GA, Norving B, Murray CJ and Roth GA; GBD 2013 Stroke Panel Experts Group: Atlas of the Global Burden of Stroke (1990-2013): The GBD 2013 Study. Neuroepidemiology 45: 230-236, 2015.
3. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, Abdulkader RS, Abdule AM, Abebo TA, Aberra SF, et al; GBD 2016 Disease and Injury Incidence and Prevalence Collaborators: Global, regional, and national incidence, prevalence, disability-adjusted life years, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 390: 1211-1259, 2017.
4. Cheung RT: The utility of melatonin in reducing cerebral damage resulting from ischemia and reperfusion. J Pineal Res 34: 153-160, 2003.
5. Zerna C, Thomalla G, Campbell BCV, Rha JH and Hill MD: Current practice and future directions in the diagnosis and acute treatment of ischemic stroke. Lancet 392: 1247-1256, 2018.
6. Leng T, Shi Y, Xiong ZG and Sun D: Proton-sensitive cation channels and ion exchangers in ischemic brain injury: New therapeutic targets for stroke? Prog Neurobiol 115: 189-209, 2014.
7. Tang XN, Liu L, Koike MA and Yenari MA: Mild hypothermia reduces tissue plasminogen activator-related hemorrhage and blood brain barrier disruption after experimental stroke. Ther Hypothermia Temp Manag 3: 74-83, 2013.
8. Tu Y, Guo C, Song F, Huo Y, Geng Y, Guo M, Bao H, Wu X and Fan W: Mild hypothermia alleviates diabetes aggravated cerebral ischemic injury via activating autophagy and inhibiting pyroptosis. Brain Res Bull 150:1-12, 2019.
9. Yang GS, Zhou XY, An XF, Liu XJ, Zhang YJ and Yu D: Mild hypothermia inhibits the Notch 3 and Notch 4 activation and seizure after stroke in the rat model. Pathol Res Pract 214:1008-1016, 2018.
10. Liu LQ, Liu XR, Zhao JY, Yan F, Wang RL, Wen SH, Wang L, Luo YM and Ji XM: Brain-selective mild hypothermia promotes long-term white matter integrity after ischemic stroke in mice. CNS Neurosci Ther 24:1275-1285, 2018.
11. Yuan Y, Zha H, Rangarajan P, Ling EA and Wu C: Anti-inflammatory effects of Edaravone and Scutellarin in activated microglia in experimentally induced ischemia injury in rats and in BV-2 microglia. BMC Neurosci 15:125, 2014.
12. Li L, Yang R, Li P, Lu H, Hao J, Li L, Tucker D and Zhang Q: Combination Treatment with Methylene Blue and Hypothermia in Global Cerebral Ischemia. Mol Neurobiol 55:2042-2055, 2018.
13. Shibuta S, Varathan S, Kamibayashi T and Mashimo T: Small temperature variations alter edaravone-induced neuroprotection of cortical cultures exposed to prolonged hypoxic episodes. Br J Anaesth 104:52-58, 2010.
14. Dodson M, de la Vega MR, Cholianas AB, Schmidlin CJ, Chapman E and Zhang DD: Modulating NRF2 in Disease: Timing Is Everything. Annu Rev Pharmacol Toxicol 59:555-579, 2019.
15. Shou L, Bei Y, Song Y, Wang L, Ai L, Yan Q and He W: Nrf2 mediates the protective effect of edaravone after chlorpyrifos-induced nervous system toxicity. Environ Toxicol 34:626-633, 2019.
16. Li C, Mo Z, Lei J, Li H, Fu R, Huang Y, Luo S and Zhang L: Edaravone attenuates neuronal apoptosis in hypoxic-ischemic brain damage rat model via suppression of TRAIL signaling pathway. Int J Biochem Cell Biol 99:169-177, 2018.
17. Cen J, Zhao N, Huang WW, Liu L, Xie YY, Gan Y, Wang CJ and Ji BS: Polyamine analogue QMA attenuated ischemic injury in MCAO rats via ERK and Akt activated Nrf2/HO-1 signaling pathway. Eur J Pharmacol 844:165-174, 2019.
18. Longa EZ, Weinstein PR, Carlson S and Cummins R: Reversible middle cerebral artery occlusion without cranietomy in rats. Stroke 20:84-91, 1989.
19. Bi M, Wang J, Zhang Y, Li L, Wang L, Yao R, Duan S, Tong S and Li J: Bone mesenchymal stem cells transplantation combined with mild hypothermia improves the prognosis of cerebral ischemia in rats. PLoS One 13: e0197405, 2018.
20. An H, Duan Y, Wu D, Yip J, Elmadhoun O, Wright JC, Shi W, Liu K, He X, Shi J, et al: Phenothiazines Enhance Mild Hypothermia-induced Neuroprotection via PI3K/Akt Regulation in Experimental Stroke. Sci Rep 7: 7469, 2017.

21. Yang GS, Zhou XY, An XF, Liu XJ, Zhang YJ and Yu D: Synergistic effect of mild hypothermia and the Notch inhibitor DAPT against post stroke seizures. Biomed Pharmacother 96: 675-684, 2017.

22. Liu S, Geng X, Forreider B, Xiao Y, Kong Q, Ding Y and Ji X: Enhanced beneficial effects of mild hypothermia by phenothiazine drugs in stroke therapy. Neurol Res 37: 454-460, 2015.

23. Dai HB, Xu MM, Lv J, Ji XJ, Zhu SH, Ma RM, Miao XL and Duan ML: Mild hypothermia combined with hydrogen sulfide treatment during resuscitation reduces hippocampal neuron apoptosis via NR2A, NR2B, and PI3K-Akt signaling in a rat model of cerebral ischemia-reperfusion injury. Mol Neurobiol 53: 4865-4873, 2016.

24. Jeffery KJ: The Hippocampus: From Memory, to Map, to Memory Map. Trends Neurosci 41: 64-66, 2018.

25. Xu F, Zhang G, Yin J, Zhang Q, Ge MY, Peng L, Wang S and Li Y: Fluoxetine mitigating late-stage cognition and neurobehavior impairment induced by cerebral ischemia reperfusion injury through inhibiting ERS-mediated neurons apoptosis in the hippocampus. Behav Brain Res 370: 111952, 2019.

26. Yang Y, Duan W, Jin Z, Yi W, Yan J, Zhang S, Wang N, Liang Z, Li Y, Chen W, et al: JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injury. J Pineal Res 55: 275-286, 2013.

27. Xia D and Zhang H: Effects of mild hypothermia on expression of NF-E2-related factor 2 and heme-oxygenase-1 in cerebral cortex and hippocampus after cardiopulmonary resuscitation in rats. Iran J Basic Med Sci 20: 1002-1008, 2017.

28. Kim SW, Lee HK, Shin JH and Lee JK: Up-down regulation of HO-1 and iNOS gene expressions by ethyl pyruvate via recruiting p300 to Nrf2 and depriving it from p65. Free Radic Biol Med 65: 468-476, 2013.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.